CERo Therapeutics to Sell Operating Subsidiary to SRX Global for $1M in Stock Plus Debt Relief

UC Davis has been activated as a clinical trial site for CER-1236, an experimental cancer treatment, and will also serve as its primary manufacturing site. This is expected to expand patient recruitment and streamline logistics. SRX Global (SRXH) announced this milestone, which follows its agreement to acquire CERo Therapeutics (CERO). Preliminary trial results show no severe adverse events, but are not yet sufficient to establish safety or efficacy.

SRX Global (SRXH) will acquire CERo Therapeutics, a cellular immunotherapy company, to accelerate development of CER-1236 for blood cancers. The deal combines SRX's public infrastructure with CERo's oncology platform, aiming to enhance capital access and operational resources. CER-1236 is in Phase 1 trials, with preliminary data showing no dose-limiting toxicities in recent cohorts. The transaction is subject to closing conditions and regulatory approvals.

Nasdaq said it will delist multiple issuers’ securities from the Nasdaq Stock Market, including CERo Therapeutics Holdings, Bowen Acquisition Corp, Graphjet Technology, Blue Hat Interactive Entertainment Technology, X3 Holdings Co, Captivision Inc, Actelis Networks, American Rebel Holdings, Reviva Pharmaceuticals, Alchemy Investments Acquisition Corp 1, Bitcoin Depot, Inotiv, GoHealth, Functional Brands, Sleep Number, Smart Digital Group, and REE Automotive. Most were suspended in 2025-2026 and

First Community Bankshares (FCBC) and Main Street Financial (MSWV) agreed to merge, expanding FCBC's operations to five states. The deal, subject to shareholder and regulatory approval, is expected to close in Q2 2027. FCBC will issue 0.6174 shares for each Main Street share. The merger aims to combine Main Street's loan growth and customer relationships with FCBC's liquidity and expanded services.

Nelson Peltz's Trian Partners reportedly offered $1.4B to acquire Wendy's, according to the Wall Street Journal. Wendy's shares rose 15% in premarket trading, with a market cap of $1.17B before the deal. Wendy's has not commented on the report.

C.H. Robinson amended its credit agreement to facilitate the acquisition of RXO, adjusting EBITDA calculations, removing cash netting caps, and maintaining a 3.75 leverage ratio. The amendment allows the deal to be treated as a permitted acquisition and includes a leverage holiday upon closing. The agreement was signed on October 22, 2026, with U.S. Bank and required lenders.